Orthopaedic sales $2,385MM, +49% (U.S. $1,274MM, +46%, ex-U.S. $1,111MM, +52%)
-
Hips +4% (U.S. +5%, ex-U.S. +4%)
-
Knees +2% (U.S. +3%, ex-U.S. +1%)
-
Trauma +4% (U.S. +2%, ex-U.S. +7%)
-
Sports Medicine +7% (U.S. +9%, ex-U.S. +4%)
-
Spine -2% (U.S. -7%, ex-U.S. +6%)
Excluding Synthes/trauma divestiture, growth +3% (U.S. +3%, ex-U.S. +4%)
Overall worldwide pricing -1%
-
U.S. hip pricing -3.5%, mix +1.5%
-
U.S. knee pricing -1%, mix +1.5%
-
U.S. spine pricing -3%, mix +2.5%
-
U.S. primary stem platform sales strong, partially offset by price pressure
-
Favorable initial response to Attune knee launch
-
Trauma growth fueled by Europe and emerging markets, notably China
-
Strong spine growth in Asia Pacific, Canada, Latin America
-
Consolidated external manufacturing/materials suppliers by ~1/3 over the last 3 years
